494 Expert group decision making for pharmacogenomic testing in Ontario
OBJECTIVES/GOALS: There is a need to better understand how governments develop strategies to adopt, evaluate, and implement novel health technologies in a public healthcare system. The goal of this project is to understand this strategy development process for the translation of pharmacogenomic (PGx...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2024-04-01
|
| Series: | Journal of Clinical and Translational Science |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866124004205/type/journal_article |
| _version_ | 1827296056157667328 |
|---|---|
| author | Samuel Neumark Mary Schmitz Ayeshah G. Mohiuddin Daniel Gillespie Zubin Austin Richard Foty Joseph Ferenbok |
| author_facet | Samuel Neumark Mary Schmitz Ayeshah G. Mohiuddin Daniel Gillespie Zubin Austin Richard Foty Joseph Ferenbok |
| author_sort | Samuel Neumark |
| collection | DOAJ |
| description | OBJECTIVES/GOALS: There is a need to better understand how governments develop strategies to adopt, evaluate, and implement novel health technologies in a public healthcare system. The goal of this project is to understand this strategy development process for the translation of pharmacogenomic (PGx) testing in Ontario, Canada. METHODS/STUDY POPULATION: This observational case study of the Ontario Health PGx Working Group focused on developing recommendations for a PGx testing implementation strategy in the province. The group included 9 individuals affiliated with Ontario Health and 13 healthcare experts from multiple clinical fields. Ontario Health is the government agency that oversees provincial healthcare planning and service delivery. Guided by the Translational Thinking Framework and qualitative research methods, we observed the working group’s activities for eight months. We collected meeting recordings, slideshow decks, emails, and group characteristics. We used descriptive statistics and a nine-step inductive approach to analyze the data to create process maps, a case report, and key decision summaries. RESULTS/ANTICIPATED RESULTS: There were 19 meetings conducted remotely with videoconferencing technology. Throughout the working group’s activities, we identified 15 key decisions related to either administrative processes or PGx scientific content. We further stratified these two categories into four main themes relating to decisions about 1) membership involvement, 2) logistical management, 3) discussion and recommendation scope, and 4) information dissemination. These four decision themes represent tools by which Ontario Health guided the expert group activities and achieved their goal of generating a strategic roadmap for PGx testing implementation in Ontario. DISCUSSION/SIGNIFICANCE: The Ontario government makes decisions about how expert groups function by monitoring and controlling the group’s activities to ensure efficiency, standardization, and practicality. Describing expert group decision-making increases transparency and highlights the critical role they play in the translational pathway of health technologies. |
| first_indexed | 2024-04-24T14:32:34Z |
| format | Article |
| id | doaj.art-e4fa81a7981f4c4a93b824fdea636a8e |
| institution | Directory Open Access Journal |
| issn | 2059-8661 |
| language | English |
| last_indexed | 2024-04-24T14:32:34Z |
| publishDate | 2024-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | Journal of Clinical and Translational Science |
| spelling | doaj.art-e4fa81a7981f4c4a93b824fdea636a8e2024-04-03T02:00:25ZengCambridge University PressJournal of Clinical and Translational Science2059-86612024-04-01814614610.1017/cts.2024.420494 Expert group decision making for pharmacogenomic testing in OntarioSamuel Neumark0Mary Schmitz1Ayeshah G. Mohiuddin2Daniel Gillespie3Zubin Austin4Richard Foty5Joseph Ferenbok6Translational Research Program, Department of Laboratory Medicine and Pathobiology, University of TorontoUniversity of TorontoThe Centre for Addiction and Mental HealthOntario HealthUniversity of TorontoUniversity of TorontoUniversity of TorontoOBJECTIVES/GOALS: There is a need to better understand how governments develop strategies to adopt, evaluate, and implement novel health technologies in a public healthcare system. The goal of this project is to understand this strategy development process for the translation of pharmacogenomic (PGx) testing in Ontario, Canada. METHODS/STUDY POPULATION: This observational case study of the Ontario Health PGx Working Group focused on developing recommendations for a PGx testing implementation strategy in the province. The group included 9 individuals affiliated with Ontario Health and 13 healthcare experts from multiple clinical fields. Ontario Health is the government agency that oversees provincial healthcare planning and service delivery. Guided by the Translational Thinking Framework and qualitative research methods, we observed the working group’s activities for eight months. We collected meeting recordings, slideshow decks, emails, and group characteristics. We used descriptive statistics and a nine-step inductive approach to analyze the data to create process maps, a case report, and key decision summaries. RESULTS/ANTICIPATED RESULTS: There were 19 meetings conducted remotely with videoconferencing technology. Throughout the working group’s activities, we identified 15 key decisions related to either administrative processes or PGx scientific content. We further stratified these two categories into four main themes relating to decisions about 1) membership involvement, 2) logistical management, 3) discussion and recommendation scope, and 4) information dissemination. These four decision themes represent tools by which Ontario Health guided the expert group activities and achieved their goal of generating a strategic roadmap for PGx testing implementation in Ontario. DISCUSSION/SIGNIFICANCE: The Ontario government makes decisions about how expert groups function by monitoring and controlling the group’s activities to ensure efficiency, standardization, and practicality. Describing expert group decision-making increases transparency and highlights the critical role they play in the translational pathway of health technologies.https://www.cambridge.org/core/product/identifier/S2059866124004205/type/journal_article |
| spellingShingle | Samuel Neumark Mary Schmitz Ayeshah G. Mohiuddin Daniel Gillespie Zubin Austin Richard Foty Joseph Ferenbok 494 Expert group decision making for pharmacogenomic testing in Ontario Journal of Clinical and Translational Science |
| title | 494 Expert group decision making for pharmacogenomic testing in Ontario |
| title_full | 494 Expert group decision making for pharmacogenomic testing in Ontario |
| title_fullStr | 494 Expert group decision making for pharmacogenomic testing in Ontario |
| title_full_unstemmed | 494 Expert group decision making for pharmacogenomic testing in Ontario |
| title_short | 494 Expert group decision making for pharmacogenomic testing in Ontario |
| title_sort | 494 expert group decision making for pharmacogenomic testing in ontario |
| url | https://www.cambridge.org/core/product/identifier/S2059866124004205/type/journal_article |
| work_keys_str_mv | AT samuelneumark 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT maryschmitz 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT ayeshahgmohiuddin 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT danielgillespie 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT zubinaustin 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT richardfoty 494expertgroupdecisionmakingforpharmacogenomictestinginontario AT josephferenbok 494expertgroupdecisionmakingforpharmacogenomictestinginontario |